Jun. 25 at 4:17 PM
Next week will be an interesting test of Dawn's capabilities as a CEO. Q2 will be over and the company will have a good read on Q2 sales. If they are good (and based on April coming in 10% higher than March, they should be), Dawn will have the opportunity to pre-announce Q2 sales. If she doesn't then she is more of a sales/marketing type not a CEO. Geron is a small biotech, and there are limited opportunities to put out press releases between earnings calls. The ones on the horizon this year include an EU partner, UK approval, EU country agreements on pricing, possible clinical trial updates on AML and the MF combo trial, and possibly a new CEO. I've omitted a sale of the company because while that is possible, it is the ultimate press release and all others won't matter
When you have an opportunity to flip the narrative with positive sales growth and beat analysts' estimates, it should be done ASAP rather than wait 5 weeks for the next earnings call.
Credit tripsdad from ymb
$GERN